Gondwanaland
Senior Member
- Messages
- 5,100
I thought they gave it to restless babies in South AfricaRooibos tea increases T 43%.
Edit -- http://examine.com/supplements/rooibos/
Last edited:
I thought they gave it to restless babies in South AfricaRooibos tea increases T 43%.
I haven't tried it, i only quitted Choline two days ago.
Everyone has a risk of developing everything. But that one is almost certainly irrelevant to NAFLD. It was probably included in a study in NAFLD, but is never mentioned, which indicates it had no correlation with NAFLD. It's also very common and not on or anywhere near a gene.Could you tell me -based on your knowledge- whether we can conclude that a CEU individual having (G;G) for rs10067427 has risk to develop NAFLD?
SNPedia is not a good source of information. http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=rs10067427 is a much better starting point.
Just wanted to tell you that i am back on being myself. No Symptoms whatsoever.
TUDCA and Choline may have a synergistic effect.
My current regimen is as follows :
08:00 : FMN, Dibencozide, Biotin, Metafolin
10:00 Choline, Inositol
<White Beans for Molybdenum, Banana for Potassium>
12:00 TUDCA, P5P, Selenium
16:00 Choline, Inositol, Vitamin C
20:00 Choline, Inositol, Selenium
24:00 TUDCA
So TUDCA + Choline stays, i think the next one to go is Inositol.
FYI : The Choline i take is Alpha-GPC
I will keep you all posted.
rs1076540 does have research supporting the data in the table here - each C allele was found to be associated in a 4.8% increase in liver GGT levels, on average. Though I don't have the statistics background to know if their corrections for multiple comparisons (the entire genome) are sufficient.
But since that is the only study so far involving that SNP, I'd consider it to be pretty weak evidence. They probably need to replicate it, this time looking at only the 1,304 SNPs they found to have a significant impact, instead of all 3 billion SNPs on the human genome. And while there isn't much known about the gene it's on thus far, there's no other indication that it's involved with liver function at all.
In any case, the large majority of people have the "risky" type, so it's a bit silly to characterize it as being risky. It's more accurate to say that the rarer version is beneficial for the lucky few who have it. The 70% with CC are just normal, and CT and TT are better than normal.
Based on http://www.ncbi.nlm.nih.gov/pubmed/21612516 , it's actually the minor allele of rs10491334 (T) which has been found to be correlated to reduced longevity, and reduced levels of CAMKIV when homozygous (TT).
rm(list=ls())
library(gwascat)
d <- read.table("path_to_your_genome.txt", sep="\t", header=FALSE,colClasses=c("character", "character", "numeric", "character"),col.names=c("rsid", "chrom", "position", "genotype"))
tmp <- d$chrom
d$chrom = ordered(d$chrom, levels=c(seq(1, 22), "X", "Y", "MT"))
## It's never a bad idea to check your work
stopifnot(all(as.character(tmp) == as.character(d$chrom)))
data("gwrngs38")
gwrngs.emd <- as.data.frame(elementMetadata(gwrngs38))
dm <- merge(d, gwrngs.emd, by.x="rsid", by.y="SNPs")
risk.alleles <- gsub("[^\\-]*-([ATCG?])", "\\1", dm$Strongest.SNP.Risk.Allele)
i.have.risk <- mapply(function(risk, mine) {risk %in% unlist(strsplit(mine, ""))}, risk.alleles, dm$genotype)
dm$i.have.risk <- i.have.risk
my.risk <- dm[dm$i.have.risk, ]
rel.cols <- c(colnames(d), "Disease.Trait", "Risk.Allele.Frequency","p.Value","OR.or.beta", "X95..CI..text.","Strongest.SNP.Risk.Allele", "i.have.risk")
##NOTE Below : I am from Europe, therefore i chose "European" on the next line. If you are from US change to "American"
risks<-head(my.risk[grep("European", my.risk$Initial.Sample.Size), rel.cols], 300)
#risks<-head(my.risk[order(my.risk$Risk.Allele.Frequency), rel.cols], 50)
orderedrisks<-print(risks[order(risks[8],decreasing=T),])
write.csv(file='YOUR_DISK_PATH/riskalleles.csv', x=orderedrisks)
Just finished a new round of Analysis. We have two new Topics that appear on the top places, namely :
-NAD(P)H Dehydrogenase (quinone) 1 - (NQO1)
-Antioxidant Response Element (ARE)
View attachment 13102
See more
https://en.wikipedia.org/wiki/NAD(P)H_dehydrogenase_(quinone_1)
Here are the PubMed Topics under consideration :
@mariovitali
Both products contain choline Bitartate, the choline only product is twinlab brand and the choline/inositol is
vitamin shoppe brand. Really bizarre that the one without inositol would have this effect. I remember a few years back when I was in a bit better shape I took alpha gpc and it worked pretty well for me, but when I tried it again last year it made me very fatigued. I will go back to the choline/inositol for the time being at a low dosage.
If i am not mistaken, you stopped TUDCA, is this correct?
I had stopped it for a couple days last week due to an IBS type flare-up, however I restarted on saturday with no ill effects.
Urolithiasis is a significant clinical problem in human and
veterinary medicine (2, 3, 19, 27, 28, 37), but the role of dietary
racemic bitartaric acid in this disease is only now becoming
appreciated.Levotartaric acid is a natural and soluble form found
in many foods and certain wines. This l isomer is excreted by
the kidney and appears to be biologically inert, but the racemic
version (dl) accumulates in the kidney and induces structural
changes consistent with crystalluria, a precursor of urolithiasis
(4, 6, 10). As evidenced in the outbreak described here, racemic
bitartaric acid is a potent inducer of urolithiasis. By the time
breeder (F0) rats in the present study were 28 months old and
their offspring (F1 rats) were 16 to 19 months old, the mortality
rate was nearly 30%.